AI Regulatory Approval Risk Assessment Playbook

A $1.4B health system is acquiring a 3-hospital regional system. The combined entity would hold 62% of the acute care market in the primary service area. FTC has challenged 6 of the last 12 health system mergers in concentrated markets. The deal was signed 3 months ago; the HSR waiting period was cleared but DOJ has issued a second request.

When to use this playbook

• Use this playbook when the decision looks like the situation above: A $1.4B health system is acquiring a 3-hospital regional system.
• It is a fit when you have source files in hand and need a structured, reviewable analysis — not a generic chat answer about "Regulatory Approval Risk Assessment".
• Do not use it as a substitute for licensed, legal, clinical, or authorized official judgment in the domain.

What you'll need

• Market share analysis by service line and geography
• DOJ second request (scope and document categories)
• FTC guidance on health system mergers and recent enforcement actions
• Academic and health policy research on concentration effects in this market
• Deal timeline and break-up fee provisions

Attachments: Documents (Documents)

You are an antitrust counsel assessing regulatory approval risk for a health system merger. I am attaching:

Work only from the attached source files. If a conclusion is not supported, say so.

Produce:
1. Assess the DOJ's theory of harm: what is the likely competitive concern given 62% market share and recent enforcement history?
2. Identify the strongest defense arguments: are there out-of-market competitors, payor contracting constraints, or quality improvement theories that counter the concentration concern?
3. Estimate the probability of a DOJ challenge and the likely outcome: consent decree with divestiture, consent decree with behavioral remedies, or blocked.
4. Assess the divestiture risk: if DOJ requires divestiture, which hospital(s) would likely be required, and what is the deal value impact?
5. Tell me the deal strategy: fight, negotiate consent decree, or walk away—and what the break-up fee analysis says about the walk-away decision.

Call out where independent models are likely to disagree, and list follow-up documents a reviewer should request.

What to expect

• DOJ theory of harm analysis
• Defense argument assessment with strength ratings
• DOJ challenge probability and outcome scenarios
• Divestiture scenario and deal value impact
• Deal strategy recommendation with break-up fee analysis

Review before you act

• Validate this output against source files before relying on it: Assess the DOJ's theory of harm: what is the likely competitive concern given 62% market share and recent enforcement history?.
• Validate this output against source files before relying on it: Identify the strongest defense arguments: are there out-of-market competitors, payor contracting constraints, or quality improvement theories that counter the concentration concern?.
• Validate this output against source files before relying on it: Estimate the probability of a DOJ challenge and the likely outcome: consent decree with divestiture, consent decree with behavioral remedies, or blocked.
• Validate this output against source files before relying on it: Assess the divestiture risk: if DOJ requires divestiture, which hospital(s) would likely be required, and what is the deal value impact?.
• Confirm every cited figure, date, counterparty, or requirement against the attached originals — models compress and can drop a qualifier.
• Treat disagreement between models as a review item, especially on classification, materiality, and recommended next action.
• Do not authorize an operational, clinical, legal, credit, or enforcement action solely because the models agree.